A Retrospective Study of Psychotropic Drug Treatments in Bipolar Disorder at Acute and Maintenance Episodes

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2023 Feb 24

PMID 36824669

Authors

Pan Jing

Jianjun Su

Chengying Zheng

Xi Mei

Xiaobin Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Bipolar disorder (BD) is predominantly treated with psychotropic drugs, but BD is a complex medical condition and the contribution of psychotropic drugs is not clear. The objectives of this study are: (1) to present psychotropic drugs used in patients with BD; (2) to access changes of psychotropic drug treatments in acute and maintenance episodes.

Methods: The study retrospectively evaluated the medical records of inpatients in the Ningbo Kangning Hospital from January 2019 to December 2019. The medical history of each subject was collected completely, including sociodemographic (gender, age, marital status, and so on) and clinical characteristics at baseline and within 12 months of admission.

Results: The study ultimately included 204 patients with BD. After 12 months, 73.0% of the patients still took drugs. Mood stabilizers (72-90%) and antipsychotics (77-95%) were still the most important drugs in patients with BD. Antidepressants (34-40%) and benzodiazepines (20-34%) were the other frequently used drug classes. For mood stabilizers, 40-56% of patients were prescribed lithium. For antipsychotic, 54-65% of patients were prescribed quetiapine. Sertraline (6-9%) and fluoxetine (5-9%) were the antidepressant that most frequently prescribed. Lorazepam (10-18%) was the most commonly used benzodiazepine. In psychotropic polypharmacy, the most frequently taken was mood stabilizer plus antipsychotic co-treatment, about 36-44% of all patients. A total of 35-48% of patients treated by two psychotropic drugs and 24-36% received three.

Conclusion: The first 6 months after treatment is very important to medication adherence. Mood stabilizers and antipsychotic remained the primary treatment for BD. Antipsychotic is on the rise in the treatment of BD.

Citing Articles

Comprehensive bibliometric analysis of pharmacotherapy for bipolar disorders: Present trends and future directions.

Chen B, Liu L, Lin F, Zeng H, Huang H, Zhang C World J Psychiatry. 2025; 15(1):100685.

PMID: 39831017 PMC: 11684214. DOI: 10.5498/wjp.v15.i1.100685.

References

Woo Y, Yoon B, Song J, Seo J, Nam B, Lee K . Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study. PLoS One. 2020; 15(1):e0227217. PMC: 6953788. DOI: 10.1371/journal.pone.0227217. View

Du N, Zhou Y, Zhang X, Guo J, Sun X . Do some anxiety disorders belong to the prodrome of bipolar disorder? A clinical study combining retrospective and prospective methods to analyse the relationship between anxiety disorder and bipolar disorder from the perspective of biorhythms. BMC Psychiatry. 2017; 17(1):351. PMC: 5655950. DOI: 10.1186/s12888-017-1509-6. View

Yatham L, Kennedy S, Parikh S, Schaffer A, Bond D, Frey B . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20(2):97-170. PMC: 5947163. DOI: 10.1111/bdi.12609. View

Rosenblat J, Simon G, Sachs G, Deetz I, Doederlein A, DePeralta D . Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2018; 243:116-120. DOI: 10.1016/j.jad.2018.09.027. View

Mojtabai R, Olfson M . National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010; 67(1):26-36. DOI: 10.1001/archgenpsychiatry.2009.175. View

Baek J, Ha K, Yatham L, Chang J, Ha T, Jeon H . Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines. J Clin Psychopharmacol. 2014; 34(5):577-87. DOI: 10.1097/JCP.0000000000000175. View

Galling B, Garcia M, Osuchukwu U, Hagi K, Correll C . Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf. 2015; 14(8):1181-99. DOI: 10.1517/14740338.2015.1053457. View

Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R . Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006; 8(3):232-41. DOI: 10.1111/j.1399-5618.2006.00314.x. View

Grande I, Goikolea J, de Dios C, Gonzalez-Pinto A, Montes J, Saiz-Ruiz J . Occupational disability in bipolar disorder: analysis of predictors of being on severe disablement benefit (PREBIS study data). Acta Psychiatr Scand. 2012; 127(5):403-11. DOI: 10.1111/acps.12003. View

10.

Levin J, Krivenko A, Howland M, Schlachet R, Sajatovic M . Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review. CNS Drugs. 2016; 30(9):819-35. DOI: 10.1007/s40263-016-0368-x. View

11.

Suppes T, Leverich G, Keck P, Nolen W, Denicoff K, Altshuler L . The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord. 2002; 67(1-3):45-59. DOI: 10.1016/s0165-0327(01)00432-3. View

12.

Carlborg A, Ferntoft L, Thuresson M, Bodegard J . Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study. Bipolar Disord. 2014; 17(1):76-85. DOI: 10.1111/bdi.12234. View

13.

Merikangas K, Jin R, He J, Kessler R, Lee S, Sampson N . Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011; 68(3):241-51. PMC: 3486639. DOI: 10.1001/archgenpsychiatry.2011.12. View

14.

Canada Y, Sabater A, Sierra P, Balanza-Martinez V, Berk M, Dodd S . The effect of concomitant benzodiazepine use on neurocognition in stable, long-term patients with bipolar disorder. Aust N Z J Psychiatry. 2020; 55(10):1005-1016. DOI: 10.1177/0004867420969819. View

15.

Bauer M, Glenn T, Alda M, Sagduyu K, Marsh W, Grof P . Drug treatment patterns in bipolar disorder: analysis of long-term self-reported data. Int J Bipolar Disord. 2014; 1:5. PMC: 4230449. DOI: 10.1186/2194-7511-1-5. View

16.

Kessing L, Vradi E, Andersen P . Life expectancy in bipolar disorder. Bipolar Disord. 2015; 17(5):543-8. DOI: 10.1111/bdi.12296. View

17.

Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa T . Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs. 2014; 28(11):989-1003. DOI: 10.1007/s40263-014-0197-8. View

18.

Harrison P, Geddes J, Tunbridge E . The Emerging Neurobiology of Bipolar Disorder. Trends Neurosci. 2017; 41(1):18-30. PMC: 5755726. DOI: 10.1016/j.tins.2017.10.006. View

19.

Williams A, Lai Z, Knight S, Kamali M, Assari S, McInnis M . Risk Factors Associated With Antidepressant Exposure and History of Antidepressant-Induced Mania in Bipolar Disorder. J Clin Psychiatry. 2018; 79(3). DOI: 10.4088/JCP.17m11765. View

20.

Grunze H, Vieta E, Goodwin G, Bowden C, Licht R, Azorin J . The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2017; 19(1):2-58. DOI: 10.1080/15622975.2017.1384850. View